Compare OMH & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OMH | CYCN |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.6M | 7.6M |
| IPO Year | 2023 | N/A |
| Metric | OMH | CYCN |
|---|---|---|
| Price | $0.81 | $1.37 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 43.4K | 41.0K |
| Earning Date | 04-17-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,264,748.00 | $2,855,000.00 |
| Revenue This Year | $28.40 | N/A |
| Revenue Next Year | $23.07 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 78.86 | ★ 1371.65 |
| 52 Week Low | $0.59 | $1.16 |
| 52 Week High | $5.10 | $6.25 |
| Indicator | OMH | CYCN |
|---|---|---|
| Relative Strength Index (RSI) | 42.57 | 42.78 |
| Support Level | $0.80 | $1.16 |
| Resistance Level | $0.84 | $1.51 |
| Average True Range (ATR) | 0.06 | 0.09 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 22.99 | 42.58 |
Ohmyhome Ltd is a data and technology-driven property technology company based in Singapore. Through its subsidiaries, it operates a one-stop-shop property platform that provides end-to-end property solutions and services for its customers, which comprises brokerage services and emerging and other services, such as home renovation and furnishing services, listing and research, mortgage referral, legal services, and insurance referral services. The company derives its revenues from two sources: revenue from brokerage services, property management services, and revenue from emerging and other services.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.